Disclosure: This article on Sleep Aids features affiliate links for OTC and prescription options, yet our honest, independent reviews remain unbiased to ensure you receive
Sleep Aids: Prescription vs OTC Options, Benefits, and Risks
Over-the-counter sleep aids are easier to buy, not automatically safer than prescriptions. Most FDA-monograph OTC sleep products use sedating first-generation antihistamines—diphenhydramine or doxylamine—intended for occasional sleeplessness. They can cause next-day impairment, tolerance, dry mouth, constipation, urinary retention, confusion, and falls. Prescription treatments target different systems and may be more appropriate for diagnosed chronic insomnia, but they also carry risks and require individualized selection.
Cognitive behavioral therapy for insomnia (CBT-I) is the leading long-term treatment for chronic insomnia because it improves sleep without nightly drug exposure. Medication can be appropriate when symptoms are severe, when CBT-I is unavailable or still taking effect, or for a specific clinical pattern. The prescriber should evaluate sleep apnea, restless legs, circadian disorders, mood conditions, pain, substances, and medications before choosing a hypnotic.
Options at a glance
| Category | Examples | Potential use | Major limitations |
|---|---|---|---|
| OTC antihistamines | Diphenhydramine (ZzzQuil/Benadryl ingredient), doxylamine (some Unisom) | Occasional difficulty falling asleep | Tolerance, anticholinergic effects, next-day impairment |
| Melatonin supplement | USP-verified products where available | Selected circadian timing problems | Variable quality, timing-sensitive, not a universal insomnia sedative |
| Orexin antagonists | Daridorexant, lemborexant, suvorexant | Sleep onset and/or maintenance by product | Cost, sedation, controlled-substance status, interactions |
| Z-drugs | Zolpidem, eszopiclone, zaleplon | Onset/maintenance depending on duration and formulation | Dependence, impairment, complex sleep behaviors |
| Benzodiazepines | Temazepam, triazolam | Selected short-term situations | Tolerance, dependence, falls, cognitive/respiratory risks |
| Melatonin receptor agonist | Ramelteon | Sleep-onset insomnia | Modest effect for some; prescription cost/access |
| Low-dose tricyclic | Doxepin | Sleep-maintenance insomnia | Drug interactions and side effects; dose matters |
| Off-label sedating drugs | Trazodone, mirtazapine, quetiapine, gabapentin | Sometimes chosen for another coexisting indication | Not benign; evidence and risks vary substantially |
Our pick: Sleepio
Sleepio provides digital CBT-I through participating employers, health plans, and health systems. It is the main recommendation for chronic insomnia when eligible because it addresses the condition rather than rotating sedatives. Availability varies, and sleep scheduling should be clinician-supervised when bipolar disorder, seizure risk, untreated sleep apnea, pregnancy, severe sleepiness, or safety-sensitive work complicates treatment.
Diphenhydramine: familiar but poor for nightly use
Diphenhydramine appears in many products, including Benadryl, ZzzQuil formulations, and “PM” combinations. Read the Drug Facts panel because brand families sell products with different ingredients. The FDA OTC nighttime-sleep-aid framework labels diphenhydramine for occasional sleeplessness and directs persistent symptoms beyond two weeks to a physician.
Sedation can fade with repeated use, encouraging dose escalation. Do not increase beyond the label. High doses can cause delirium, heart rhythm problems, seizures, coma, and death. Even ordinary doses may impair driving the next morning.
Anticholinergic effects are especially problematic for older adults and people with glaucoma, enlarged prostate/urinary retention, constipation, cognitive impairment, or fall risk. Combining diphenhydramine with alcohol, opioids, benzodiazepines, cannabis, or another antihistamine compounds impairment.
Avoid combination “PM” products when the pain reliever is not needed. Unnecessary acetaminophen or NSAID exposure adds liver, kidney, stomach, bleeding, and overdose risks depending on ingredient and patient.
Doxylamine: longer-lasting sedation
Doxylamine is sold in some Unisom SleepTabs and generics, while other Unisom products contain diphenhydramine or melatonin. Never dose by brand name. Doxylamine can last long enough to cause substantial morning grogginess, dry mouth, constipation, and impaired coordination.
It has a specific clinician-directed role with pyridoxine for nausea and vomiting in pregnancy, but that does not make self-directed nightly use appropriate for all pregnant people. The exact product, dose, and indication need obstetric guidance.
Like diphenhydramine, doxylamine is not a good chronic insomnia strategy. If it is required repeatedly, the person needs an assessment and a safer durable plan.
Melatonin: a circadian tool
Melatonin can be useful for jet lag, delayed sleep-wake phase, and selected sleep-onset problems when timing is correct. It is a dietary supplement in the United States, and measured content can differ from labels. More milligrams are not necessarily more effective and can increase morning sleepiness, headache, vivid dreams, or mistimed circadian effects.
Look for USP Verified or another credible independent certification when a clinician recommends it. Avoid multi-ingredient gummies. Pregnancy, childhood, autoimmune disease, seizure conditions, anticoagulants, and other medicines require individualized advice.
Melatonin is not known for classic dependence like a benzodiazepine, but nightly psychological reliance can occur. Review ongoing need and timing rather than escalating from 3 to 5 to 10 mg.
Orexin receptor antagonists
Daridorexant (Quviviq), lemborexant (Dayvigo), and suvorexant (Belsomra) reduce wake drive by blocking orexin signaling. Indications and approved dosing address sleep onset and/or maintenance. They can be a rational option when chronic insomnia persists and the prescriber judges benefits to outweigh risks.
Adverse effects include next-day sleepiness, dizziness, unusual dreams, and possible sleep paralysis or hallucination-like experiences around sleep. Complex sleep behaviors can occur with hypnotics. These drugs are controlled substances in the United States and interact with certain CYP3A inhibitors/inducers and other depressants.
They require enough remaining sleep time and caution with driving. Narcolepsy is a contraindication because orexin deficiency is central to that disorder. Insurance coverage and prior authorization can make prices high; use the pharmacy’s actual out-of-pocket quote rather than assuming a manufacturer coupon applies.
Z-drugs
Zolpidem (Ambien and extended-release variants), eszopiclone (Lunesta), and zaleplon (Sonata) act at GABA-A receptor sites. Their durations differ: zaleplon is short acting, while extended-release zolpidem and eszopiclone may better address maintenance but increase residual exposure.
The FDA requires a boxed warning for rare serious injuries and deaths from complex sleep behaviors—sleepwalking, sleep driving, cooking, or other actions while not fully awake—with zolpidem, eszopiclone, and zaleplon. A prior complex sleep behavior is a major contraindication under labeling.
These medicines can produce dependence, rebound insomnia, memory problems, falls, and next-day impairment. Women and people with slower clearance have historically required particular dose attention for zolpidem. Never combine with alcohol or take an extra dose after waking unless the exact product is prescribed for that situation.
Benzodiazepines
Temazepam and triazolam are among benzodiazepines approved for insomnia, while others may be used off-label. They can reduce sleep latency but carry tolerance, dependence, withdrawal, falls, cognitive effects, and respiratory depression risks—especially with opioids, alcohol, or lung/sleep-disordered breathing.
Abrupt discontinuation after dependence can cause severe anxiety, rebound insomnia, tremor, perceptual changes, and seizures. Taper only under prescriber guidance. Older adults and people at fall risk are particularly vulnerable.
Benzodiazepines may have a role in selected short-term scenarios, but they should not be the automatic first answer to chronic insomnia. Refill continuity without reassessment allows the original diagnosis and risks to change unnoticed.
Ramelteon and low-dose doxepin
Ramelteon (Rozerem) stimulates melatonin receptors and is prescribed for sleep-onset insomnia. It is not a controlled substance and has a lower abuse profile than benzodiazepines/Z-drugs. Its benefit can be modest and timing still matters. Liver disease and interacting medicines require review.
Low-dose doxepin (Silenor or generic dosing) is used for sleep-maintenance insomnia through histamine receptor effects. This low dose should not be conflated with antidepressant-range tricyclic dosing, which has broader anticholinergic and cardiac effects. Prescribers review other serotonergic or monoamine-oxidase-related medicines and health conditions.
Neither drug is ideal for every pattern. A person who falls asleep easily but wakes repeatedly needs a different approach from someone with delayed circadian timing.
Off-label options
Trazodone is widely used for sleep despite limited evidence as a universal chronic-insomnia treatment. It can cause grogginess, dizziness, orthostatic hypotension, falls, and rare priapism. Mirtazapine can be useful when depression, low appetite, or another indication exists, but may cause weight gain and daytime sedation.
Quetiapine has substantial metabolic, cardiovascular, movement, and other risks and should not be treated as a casual sleeping pill. Gabapentin may be chosen for neuropathic pain, restless legs in selected contexts, or other indications; it causes dizziness/sedation and can interact dangerously with opioids and respiratory risk.
Medication that happens to sedate is not automatically appropriate insomnia treatment. The coexisting diagnosis should justify exposure.
How a clinician chooses
The evaluation distinguishes difficulty initiating sleep, maintaining sleep, early awakening, insufficient opportunity, and circadian mismatch. It reviews duration, daytime impairment, schedule, naps, caffeine, alcohol, cannabis, breathing symptoms, leg sensations, mental health, menopause, pain, and shift work.
The clinician checks current drugs and supplements, pregnancy status, age, liver/kidney function, fall risk, substance-use history, and occupation. A pilot needs a target, lowest effective dose, duration, monitoring, and exit plan. Driving and emergency-care responsibilities matter.
When medication is the wrong first move
Loud snoring, gasping, witnessed pauses, morning headache, or excessive sleepiness suggests sleep apnea. Sedatives can worsen breathing or blunt awareness. An urge to move the legs at night suggests restless legs, which requires iron/medication evaluation. A progressively later sleep schedule calls for circadian treatment.
Mania, severe depression, suicidality, substance withdrawal, or medication toxicity needs urgent targeted care. New severe pain, shortness of breath, neurological symptoms, or pregnancy complications should not be sedated away.
OTC products are reasonable only for an appropriate adult with occasional sleeplessness who reads the label and has no contraindication. Chronic insomnia deserves CBT-I and diagnosis. Prescription therapy can be safer and more rational than indefinite antihistamine use when a clinician selects and monitors it—but no sleeping pill replaces evaluation.